Scottish biotech business ILC Therapeutics has signed a research and development partnership with veterinary group Dechra Pharmaceuticals.
The deal will see Dechra develop ILC’s Caniferon product to treat atopic dermatitis in dogs.
Atopic dermatitis is the most common form of eczema affecting humans and canines, with the global canine market for atopic dermatitis estimated to exceed $1bn.